The association between codon72 polymorphism of p53 gene and the risk of endometrial cancer: an updating meta-analysis

Archives of Gynecology and Obstetrics

Volumn 294, Issue 2, 2016, Pages 353-359

  Lin, Xinzi ^a   Hou, Dabiao ^a   Huang, Chenlingzi ^a   Luo, Xin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

Author keywords

Endometrial cancer; Meta analysis; p53; Polymorphism

Indexed keywords

ARTICLE; CANCER RISK; CARCINOGENESIS; CODON; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ACTIVITY; ENDOMETRIUM CANCER; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; RISK ASSESSMENT; RISK FACTOR; TUMOR SUPPRESSOR GENE; ALLELE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; ENDOMETRIUM TUMOR; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; RISK;

CODON; PROTEIN P53;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CODON; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, GENETIC; RISK; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84953403896     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-015-4005-6     Document Type: Article

References (43)

1. Sorosky JI (2008) Endometrial cancer. Obstet Gynecol 111(2 Pt 1):436–447. doi:10.1097/AOG.0b013e318162f690
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. Ca Cancer J Clin 63(1):11–30
3. Cancer Research UK. Uterine cancer incidence statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/uterus/incidence/. Accessed 26 Apr 2015
4. Galaal K, Al Moundhri M, Bryant A, Lopes AD, Lawrie TA (2014) Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database Syst Rev 5:CD010681. doi:10.1002/14651858.CD010681.pub2
5. Murali R, Soslow RA, Weigelt B (2014) Classification of endometrial carcinoma: more than two types. Lancet Oncol 15(7):e268–e278. doi:10.1016/s1470-2045(13)70591-6
6. Fornasarig M, Campagnutta E, Talamini R, Franceschi S, Boz G, Scarabelli C, Andreaus CM, Scozzari G, Valentini M (1998) Risk factors for endometrial cancer according to familial susceptibility. Int J Cancer 77(1):29–32
7. Lorenzo Bermejo J, Buchner FL, Hemminki K (2004) Familial risk of endometrial cancer after exclusion of families that fulfilled Amsterdam, Japanese or Bethesda criteria for HNPCC. Ann Oncol 15(4):598–604
8. Win AK, Reece JC, Ryan S (2015) Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstet Gynecol 125(1):89–98. doi:10.1097/AOG.0000000000000563
9. Britschgi C, Fey MF (2009) Tumor suppressor genes in myeloid differentiation and leukemogenesis. Future Oncol 5(2):245–257. doi:10.2217/14796694.5.2.245
10. Koshiyama M, Ueta M (2002) Two kinds of endometrial neoplasia arising from different origins in the uterine corpus: comparison of p53 expression and sex steroid receptor status. Eur J Obstet Gyn R B 104(2):167–170
11. Zajac A, Smolarz B, Stachowiak G, Wilczynski JR (2014) TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women. Med Oncol 31(11):286. doi:10.1007/s12032-014-0286-z
12. Levine AJ, Oren M (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9(10):749–758. doi:10.1038/nrc2723
13. Garcia PB, Attardi LD (2014) Illuminating p53 function in cancer with genetically engineered mouse models. Semin Cell Dev Biol 27:74–85
14. Zajac A, Stachowiak G, Smolarz B, Wilczynski JR (2013) Polymorphisms of codon 72 of the TP53 gene in endometrial carcinoma of postmenopausal women. Postepy Hig Med Dosw (Online) 67:1312–1318
15. Kataoka M, Okabayashi T, Johira H, Nakatani S, Nakashima A, Takeda A, Nishizaki M, Orita K, Tanaka N (2000) Aberration of p53 and DCC in gastric and colorectal cancer. Oncol Rep 7(1):99–103
16. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. doi:10.1002/sim.1186
17. Zubor P, Hatok J, Moricova P, Kajo K, Kapustova I, Mendelova A, Racay P, Danko J (2015) Gene expression abnormalities in histologically normal breast epithelium from patients with luminal type of breast cancer. Mol Biol Rep 42(5):977–988
18. Brachova P, Mueting SR, Carlson MJ, Goodheart MJ, Button AM, Mott SL, Dai DH, Thiel KW, Devor EJ, Leslie KK (2015) TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Int J Oncol 46(2):607–618
19. Bellini MF, Cadamuro ACT, Succi M, Proenca MA, Silva AE (2012) Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol 2012:891961
20. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T, Lu X (2006) iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72 polymorphic p53. Nat Genet 38(10):1133–1141
21. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19(2):1092–1100
22. Dumont P, Leu JIJ, Della Pietra AC, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33(3):357–365
23. Pim D, Banks L (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108(2):196–199
24. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L (1998) Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393(6682):229–234. doi:10.1038/30400
25. Malisic E, Jankovic R, Brotto K, Radulovic S (2013) TP53 codon 72 polymorphism and risk of cervical carcinoma in Serbian women. Arch Gynecol Obstet 288(3):621–625. doi:10.1007/s00404-013-2783-2
26. Kafshdooz T, Tabrizi AD, Ardabili SMM, Kafshdooz L, Ghojazadeh M, Gharesouran J, Abdii A, Alizadeh H (2014) Polymorphism of p53 Gene Codon 72 in endometrial cancer: correlation with tumor grade and histological type. Asian Pac J Cancer Prev 15(22):9603–9606. doi:10.7314/apjcp.2014.15.22.9603
27. Roh JW, Kim JW, Park NH, Song YS, Park IA, Park SY, Kang SB, Lee HP (2004) p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol 93(2):499–505. doi:10.1016/j.ygyno.2004.02.005
28. Gu Y, Zhou X, Zhang SL (2011) Meta-analysis of an association of codon 72 polymorphisms of the p53 gene with increased endometrial cancer risk. Genet Mol Res 10(4):3609–3619. doi:10.4238/2011.October.31.11
29. Khan MH, Khalil A, Rashid H (2015) Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis. Genet Res (Camb) 97:e7. doi:10.1017/S0016672315000075
30. Mitchell AA, Cutler DJ, Chakravarti A (2003) Undetected genotyping errors cause apparent overtransmission of common alleles in the transmission/disequilibrium test. Am J Hum Genet 72(3):598–610. doi:10.1086/368203
31. Jongen VHWM, Briet JM, de Jong RA, Joppe E, ten Hoor KA, Boezen HM, Evans DB, Hollema H, van der Zee AGJ, Nijman HW (2009) Aromatase, cyclooxygenase 2, HER-2/neu, and P53 as prognostic factors in endometrioid endometrial cancer. Int J Gynecol Cancer 19(4):670–676
32. Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M, Hamann U, Scott RJ (2009) Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol 113(1):109–114. doi:10.1016/j.ygyno.2008.12.036
33. Janiec-Jankowska A, Konopka B, Goluda C, Najmola U (2010) TP53 mutations in endometrial cancers: relation to PTEN gene defects. Int J Gynecol Cancer 20(2):196–202
34. Garcia-Dios DA, Lambrechts D, Coenegrachts L, Vandenput I, Capoen A, Webb PM, Ferguson K, Akslen LA, Claes B, Vergote I, Moerman P, Van Robays J, Marcickiewicz J, Salvesen HB, Spurdle AB, Amant F (2013) High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol 128(2):327–334. doi:10.1016/j.ygyno.2012.11.037
35. Esteller M, GarcÃa A, MartÃnez-Palone JM, Xercavin J, Reventà J (1997) Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer 75(9):1385–1388
36. Peller Shoshana, Halperin Rehuvit, Schneider D (1999) Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol Rep 6:193–197
37. Agorastos T, Masouridou S, Lambropoulos AF, Chrisafi S, Miliaras D, Pantazis K, Constantinides TC, Kotsis A, Bontis I (2004) P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur J Cancer Prev 13(4):277–280
38. Niwa Y, Hirose K, Matsuo K, Tajima K, Ikoma Y, Nakanishi T, Nawa A, Kuzuya K, Tamakoshi A, Hamajima N (2005) Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett 219(2):183–190. doi:10.1016/j.canlet.2004.10.018
39. Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, Nishiyama K, Yasuda M, Ueki M (2006) Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol 100(1):173–178. doi:10.1016/j.ygyno.2005.08.015
40. Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, Okamoto Y, Torii K, Noda S (2009) Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum Cell 22(4):101–106. doi:10.1111/j.1749-0774.2009.00075.x
41. Zubor P, Stanclova A, Kajo K, Hatok J, Klobusiakova D, Visnovsky J, Danko J (2009) The p53 codon 72 exon 4 BstUI polymorphism and endometrial cancer in Caucasian women. Oncology 76(3):173–183. doi:10.1159/000201570
42. Ghasemi N, Karimi-Zarchi M, Mortazavi-Zadeh MR, Atash-Afza A (2010) Evaluation of the frequency of TP53 gene codon 72 polymorphisms in Iranian patients with endometrial cancer. Cancer Genet Cytogenet 196(2):167–170. doi:10.1016/j.cancergencyto.2009.09.013
43. Yoneda T, Kuboyama A, Kato K, Ohgami T, Okamoto K, Saito T, Wake N (2013) Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. Oncol Rep 30(1):25–34. doi:10.3892/or.2013.2433